

Christos K Fountzilas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9018333/publications.pdf>

Version: 2024-02-01

33
papers

2,076
citations

623188

14
h-index

454577

30
g-index

34
all docs

34
docs citations

34
times ranked

2374
citing authors

#	ARTICLE	IF	CITATIONS
1	FL118, acting as a "molecular glue degrader"™, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control "Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	12
2	Immunotherapy in hepatocellular cancer. <i>Advances in Cancer Research</i> , 2021, 149, 295-320.	1.9	0
3	Cruciferous vegetable consumption and pancreatic cancer: A case-control study. <i>Cancer Epidemiology</i> , 2021, 72, 101924.	0.8	7
4	Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. <i>Communications Biology</i> , 2021, 4, 862.	2.0	5
5	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2021, 398, 759-771.	6.3	642
6	A phase I study of the "anaplastic lymphoma kinase" inhibitor ceritinib in combination with "gemcitabine"-based chemotherapy in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2021, 149, 2063-2074.	2.3	8
7	Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 10-15.	2.3	23
8	Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 439-457.	2.3	564
9	Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6726-6736.	3.2	8
10	Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapy. <i>American Journal of Cancer Research</i> , 2021, 11, 5190-5213.	1.4	0
11	Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Targeted Oncology</i> , 2020, 15, 85-92.	1.7	4
12	Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer. <i>Cancers</i> , 2020, 12, 3413.	1.7	12
13	Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis. <i>Liver Cancer</i> , 2020, 9, 549-562.	4.2	14
14	Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. <i>Cancer</i> , 2020, 126, 3689-3697.	2.0	11
15	Physical Inactivity and Pancreatic Cancer Mortality. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 1088-1093.	0.6	4
16	A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 963-970.	2.9	17
17	Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. <i>Clinical Cancer Research</i> , 2020, 26, 71-81.	3.2	109
18	Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 304-311.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 861.	1.7	25
20	The Highly Pure Neem Leaf Extract, SCNE, Inhibits Tumorigenesis in Oral Squamous Cell Carcinoma via Disruption of Pro-tumor Inflammatory Cytokines and Cell Signaling. <i>Frontiers in Oncology</i> , 2019, 9, 890.	1.3	30
21	Immune checkpoint inhibitors in esophagogastric cancer: still a long way to go. <i>Journal of Thoracic Disease</i> , 2019, 11, 351-353.	0.6	0
22	Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. <i>Cancers</i> , 2019, 11, 1980.	1.7	29
23	Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 202-210.	2.3	281
24	Multi-gene Panel Testing in Breast Cancer Management. <i>Cancer Treatment and Research</i> , 2018, 173, 121-140.	0.2	17
25	A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. <i>Cancer</i> , 2018, 124, 3890-3899.	2.0	5
26	A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 697-703.	1.1	61
27	A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 497-505.	1.1	13
28	Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?. <i>Investigational New Drugs</i> , 2017, 35, 386-391.	1.2	4
29	Review: Oncolytic virotherapy, updates and future directions. <i>Oncotarget</i> , 2017, 8, 102617-102639.	0.8	111
30	Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experience. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 55-63.	0.6	15
31	A rare case of ovarian carcinosarcoma with neuroendocrine differentiation. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 71-74.	0.1	4
32	Diffuse anorectal melanoma; review of the current diagnostic and treatment aspects based on a case report. <i>World Journal of Surgical Oncology</i> , 2009, 7, 64.	0.8	24
33	Spontaneous regression of a true splenic cyst: a case report and review of the literature. <i>Cases Journal</i> , 2009, 2, 8730.	0.4	9